Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals has announced that its subsidiary has commenced commercial shipment of its Omeprazole delayed-release capsules USP product in the 40mg strength from its Davie, Florida manufacturing facility.
Subscribe to our email newsletter
In conjunction with the launch, Watson has 180 days of marketing exclusivity for being the first to file an abbreviated new drug application containing a paragraph IV certification for the 40mg strength.
Watson’s Omeprazole is the generic equivalent to AstraZeneca’s Prilosec delayed-release capsules USP and is indicated for the short-term treatment of active duodenal ulcer.